SlideShare uma empresa Scribd logo
1 de 57
Baixar para ler offline
ClinicalTrials
Dr Menaal Kaushal
JR II
Department of S.P.M.
S. N. Medical College
Agra
16-05-2014
Types of Studies
Epidemiological Studies
Observational
Descriptive Analytical
Interventional/ Experimental
RCT FieldTrial
Community
Trial
16-05-2014 2
Why ClinicalTrials?
 Gold standard with aTotality of Evidence:
 Lab Study- High Precision
 Epidemiological Study- High Relevance
 Designed to elucidate Most Appropriate Treatment for the
FUTURE PATIENTS
 Should be done only in existence of CLINICAL EQUIPOISE
 So, during enrollment the researcher must ensure Absence of
THERAPEUTIC MISCONCEPTION among the participants.
 Also ensure the non-existence of Oxymoron: THERAPEUTIC
RESEARCH
16-05-2014 3
From Lab to Clinics to Community- the
Developmental Process Funnel
Drug
Discovery
Pre
clinical
Phase I
FIH
Phase II
POC
Phase III
Post
approval
Trials-
Phase IV
10,000
compounds
10- 15 yrs
$ 1 billion
1 compound
Bench to Bed SideTranslational Blocks
T0- Discovery Science T1 Phase
Clinical/Translational Research
NOT ClinicalTrial BorderlineTrial ClinicalTrial
T2 T3
16-05-2014 4
Pre Clinical Phase
 Safety Testing- Toxicity and Physiological Response to the
new Compound is assessed
 Organs targeted include:
 Cardio- vascular
 Neuro- muscular
 Respiratory
 + Other Organs and systems depending on the compound’s action
 Dose Dependence
 Potential for Reversibility16-05-2014 5
Toxicity studies
 AcuteToxicity: determine overdose effects
 Repeated Dose Toxicity: maximum duration of
clinical trial
16-05-2014 7
MRSD Determination
 HED= animal’s NOAEL (mg/kg)* Wt (Animal) 1-0.62
 A 10 fold Safety margin is usually used, so:
 MRSD= HED/ Safety factor
 Maximum tolerated Dose (MTD) needs to be
estimated where the Dose limiting toxicity has a
certain probability
( )Wt (Human)
16-05-2014 8
Dose Response Curve
Increasing Dose (mg/kg)------------>
Probabilityofadverseevents
P(DLT)---------->
0
1
0.33
MTD
16-05-2014 9
Phase I- FIHTrial
 Healthy volunteers are given a single dose in a
controlled environment (In- patient settings)
 Volunteers usually paid
 Risks are kept to be minimum
 What needs to be assessed is:
 Safety
 Pharmacokinetics
 Pharmacodynamics
 Route and Rate of administration
 Fixing up the end points
 Physiologic effects in humans16-05-2014 10
POC Study
 Patients having the disease of interest, are enrolled
 Volunteers not paid
 Moderate (or even serious) risks are acceptable
 Done to assess:
 The Dose response
 Safety
 Pathophysiology
 Limited observation about efficacy
16-05-2014 11
Steps in Conducting a Phase III Clinical
Trial
 Design Phase
 Research Question- FINER Criteria, PICOT style
 Study Designs
 Ethical Considerations& GCP Guidelines
 Registering with CTRI
 Latest DGCA Guidelines-Video Record Every Consent
 Sample Size, Clearly defined Inclusion- Exclusion
criteria
16-05-2014 12
Steps in Conducting a Phase III Clinical
Trial
 Implementation Phase
 Randomization v/s Random Allocation
 Blinding
 Control- StandardTreatment v/s Placebo
 Monitoring& DSMB- InterimAnalysis
 Analytical Phase
 ITT v/s Per protocol analysis
 CONSORT Guidelines
16-05-2014 13
Research Question
 FINER; PICOT
 Following need to be considered:
 Effect Size
 Composite endpoints
 Surrogate End Points
 Study duration
 Secondary Questions
 Sub group Hypothesis
 Natural History Studies
16-05-2014 14
Study Designs
 Two group parallel design-The Look ahead trial (T2DM obese
pts on Diabetes support& education v/s active, intensive
lifestyle modification)
 Multi group parallel design-The Re-ly trial (Atr Fib pts on
warfarin v/s dabigatran 110mg v/s dabigatran 150 mg)
 Factorial design-The SUPPORTTrial (very premature neonates
were randomized into Early surfactant v/s early CPAP and O2
Saturation 85% v/s 95%)
 Cross over design- Pts can be compared on themselves. E.g.
Hemophilia trial. No carry over between the two treatment
periods- Rest period is needed16-05-2014 15
The History Behind Ethics
Nuremberg Code- 1946
Declaration of Helsinki- 1964
Council for International Organizations of
Medical SciencesCIOMS- 1982
International Conference on Harmonization
– Good clinical practice (ICH-GCP)- 1996
16-05-2014 16
Historical Perspectives
 Council for International Organizations of Medical
Sciences (CIOMS) and WHO (1982) – International
ethical guidelines for biomedical research involving
human subjects
 Revised – 1993, 2002
 International Conference of Harmonization – Good
clinical practice (ICH-GCP)-1996)
 International ethical and scientific quality standard for
designing, conducting, recording and reporting trials involving
human subjects.
16-05-2014 18
13 Principles of GCP
1. Ethics (Declaration of Helsinki)
2. Risk Benefit analysis
3. Trial subjects (rights and safety)
4. Investigational product (Information support
study)
5. Scientifically sound
6. Compliance (IRB review)16-05-2014 19
7. Qualified physician to provide medical care
8. Trial staff (trained in protocol)
9. Informed consent
10. Data (reporting, interpretation, verification)
11. Confidentiality
12. Good manufacturing practice of the
investigational product
13. QualityAssurance of all aspects of protocol
16-05-2014 20
7 Components of the Ethics:
1. Social or Scientific value
2. ScientificValidity
3. Fair Subject Selection
4. Favorable risk- benefit ratio
5. Independent review
6. Informed Consent
7. Respect for potential and enrolled subjects
16-05-2014 21
Ethics in Trials
 During Phase I Trials, 95% of the times,
participating patients do not benefit from theTrial
 The probability (chance) of having any benefit 5%
 Risk of fatal complication 5%
 While there may be a significant chance of benefit in
Phase IIITrial
16-05-2014 22
Risk- Benefit Ratio
16-05-2014 23
Risk- Benefit Ratio
16-05-2014 24
Informed Consent - Elements
 Information
 Patient/subject information sheet
 Comprehension
 Simple and understandable language
 Local language translations
 Voluntariness
 Consent
16-05-2014 27
Informed Consent
 Community studies – Consent needed from
 Community – group consent
 Individuals
 Children
 Parent/guardian
 Assent of child to his/her capability
 Mentally Ill
 Close biological relative
 Legally authorized person
 Certificate from psychiatrist
16-05-2014 28
Importance Of Clinical Trials Registration
 To ensure transparency , accountability and to
increase public trust in the conduct of clinical
research.
 Clinical trial registration and results reporting
would help ensure unbiased public records on
safety and efficacy of drugs.
 All clinical trials should be registered before the
enrolment of the first patient and all results made
publicly available.
16-05-2014 29
Registration of Trials Globally
 At the 58th WHA held on 25th May 2005 WHO had set up of an
International Clinical Trial Registry Platform (ICTRP), a one-stop
search portal for searching registers worldwide.
 The ICTRP recommended 20 key points as Trial Registration
data Set that need to be publicly declared before the enrolment
of the first patient.
 In the 59th General Assembly of the World Medical Association,
2008, in its revision of the Declaration of Helsinki among other
modifications, specifies that:
 “Every clinical trial must be registered in a publicly accessible
database before recruitment of the first subject.”
16-05-2014 30
CTR- I
 Till 2006, there was no national registry of clinical trials in
India
 On July 20, 2007, ICMR through its National Institute of
Medical Statistics (NIMS) formed Clinical Trials Registry –
India (CTRI) www.ctri.nic.in with financial support from DST
andWHO.
 The CTRI has additional data points over the ICTRP’s
recommended 20 point data set:
 Later these additional points were borrowed from CTR- I and
were inculcated in the WHO’s ICTRP.
16-05-2014 31
Registration Data Set of the CTRI
1. Public Title of Study
2. Scientific Title of Study,
Acronym, if any
3. Secondary IDs, (UTN, Protocol
No etc)
4. Principal Investigator’s Name
and Address*
5. Contact Person (Scientific
Query)
6. Contact Person (Public Query)
7. Source/s of Material or Monetary
Support
8. Primary Sponsor
9. Secondary Sponsor
10. Countries of Recruitment
11. Site/s of study
12. Name of Ethics Committee and
approval status
13. Regulatory Clearance obtained
from DCGI
* Optional fields
14.Health Condition/Problem studied
15.Study Type
16.Intervention and Comparator agent
17.Key inclusion/Exclusion Criteria
18.Method of generating
randomization sequence*
19.Method of allocation concealment*
20.Blinding and masking*
21.Primary Outcome/s
22.Secondary Outcome/s
23.Target sample size
24.Phase of Trial
25.Date of first enrollment
26.Estimated duration of trial
27.Status of Trial
28.Publication details*
29.Brief Summary
Additional items of CTRI
16-05-2014 32
ClinicalTrial Registry-India
16-05-2014
33
 It is housed at the National Institute of Medical
Statistics, ICMR, New Delhi.
 Trial registration is purely online, paperless
process and free of charge
 The CTRI software application was modified and
implemented on 15th March 2011.
Clinical Trials Registry – India
16-05-2014 34
Objectives of CTRI
 To establish a public record system by registering all
clinical trials on health products including:
 Drugs
 Devices
 Vaccines
 Herbal drugs
 It makes the information available to both public and
healthcare professionals in an unbiased, scientific and timely
manner.
 To create a complete, authentic and readily available
data of all ongoing and completed clinical trials.
16-05-2014 35
Objectives of CTRI
 To provide a corrective system against “positive results
bias” and “selective reporting” of research results to peer
review publication.
 To increase awareness and accountability of all the
participants of the clinical trials and also for public access:
 Trial registration empowers the public and offer patients the choice
of enrolling in a clinical trial to gain access to latest breakthrough
treatment options.
 To promote training, assistance and advocacy for clinical
trials by creating database and modules of study for
various aspects of clinical trials and its registration.
16-05-2014 36
Registration of clinical trials under
CTR- I is recommended by:
1. Drugs Controller General (India): Made
mandatory since June 2009
2. Editors of Indian Biomedical Journals;
3. Ethics Committees of various institutions,
AIIMS, CMC, Sir Ganga Ram Hospital etc.
16-05-2014 37
DCGI Notification
16-05-2014 38
 CTRI currently accepts registration of:
 Prospective trials
 Ongoing
 Completed trials
 Terminated trials
 Registered trials are flagged as:
 Trial registered prospectively
 Trial registered retrospectively
 Terminated trial registered
16-05-2014 41
16-05-2014
Empowering
patients
42
Registering Trials during PG Thesis
CTRI encourages registration of trials
being conducted as part of post-
graduation thesis work
 This would help
 Ensure ethical standards
 Prevent unnecessary duplicate research
 Raise the standard of research
 Enable better exchange of data and ideas
16-05-2014 47
PG Thesis registration
16-05-2014 48
Methodology
Enrollment Criteria
Ascertainment of
Primary End Point
Treatment A
(Test)
Treatment B
(Control)
Quality:
Adherence
Missing Data
16-05-2014 53
Sample Size Calculations
n= 2 ṕ (1-ṕ) (Zα/2+Zβ)2/ Δ2
Where:
Δ= pc- pt
ṕ= (pc+ pt)/ 2
At α= 0.05, Zα/2= 1.96
At β= 0.20, Zβ= 0.84
16-05-2014 54
Sample Size Calculations
n= 2 (Zα/2+Zβ)2/ log (λc/λt)2
Where:
λ= survival probability
At α= 0.05, Zα/2= 1.96
At β= 0.20, Zβ= 0.84
16-05-2014 55
Randomization
 Unrestricted Randomization: may produce
treatment groups of different sizes
 Randomized Permuted Block
 Stratified Randomized Permuted Block
 Cluster Randomization
16-05-2014 56
Unrestricted Randomization
Probability---------------------
Number of heads from 20 tosses--------------------16-05-2014 57
Relativeefficiency
Proportion allocated toTreatment A
50%0% 100%
Relative Efficiency of Unbiased Allocation
16-05-2014 58
Randomized Permuted Blocks
ABAB AABB
BBAA BABA
ABBA
BAAB
16-05-2014 59
Blinding
Single BlindTrial
Double BlindTrial
Triple BlindTrial
16-05-2014 60
Analysis
 Intent to treat
 Modified Intent to treat
 Per protocol Analysis
 On assignedTt
 Fully compliant with study domain
 As treated Analysis
Best Active- Interventional
Compromised Observational
16-05-2014 61
Analysis to Study Outcome
 Binary (HTN or Normotensive)
 Measurable (BP reading)
 Time to event (at what time during the follow up, has the
event occurred)
 Other outcomes: No. of episodes (e.g. no of exaggeration
episodes of asthma, while on treatment)
16-05-2014 62
CONSORT (Con solidated S tandards o f
R eportingT rials) statement
Section/Topic Item
No
Checklist Reported
on Pg no
Title& Abstract 1a Identification as a randomised trial in the title
1b Structured summary of trial design, methods, results,
and conclusions (for specific guidance see CONSORT
for abstracts)
Introduction 2a Scientific background and explanation of rationale
Background&
Objectives
2b Specific objectives or hypotheses
Method
Trial Design 3a Description of trial design (such as parallel, factorial)
including allocation ratio
3b Important changes to methods after trial
commencement (such as eligibility criteria), with
reasons
16-05-2014 63
Section/Topic Item
No
Checklist Report
ed on
Pg no
Participants 4a Eligibility criteria for participants
4b Settings and locations where the data were collected
Interventions 5 The interventions for each group with sufficient
details to allow replication, including how and when
they were actually administered
outcomes 6a Completely defined pre-specified primary and
secondary outcome measures, including how and
when they were assessed
6b Any changes to trial outcomes after the trial
commenced, with reasons
Sample size 7a How sample size was determined
7b When applicable, explanation of any interim analyses
and stopping guidelines16-05-2014 64
Section/Topic Ite
m
No
Checklist Reported
on Pg no
Randomization
Sequence 8a Method used to generate the random allocation
sequence
Generation 8b Type of randomisation; details of any restriction (such as
blocking and block size)
Allocation
Concealment
mechanism
9 Mechanism used to implement the random allocation
sequence (such as sequentially numbered containers),
describing any steps taken to conceal the sequence until
interventions were assigned
Implementatio
n
10 Who generated the random allocation sequence, who
enrolled participants, and who assigned participants to
interventions
Blinding 11a If done, who was blinded after assignment to
interventions (for example, participants, care providers,
those assessing outcomes) and how
16-05-2014 65
Section/
Topic
Item
No
Checklist Reported
on Pg no
11b If relevant, description of the similarity of interventions
Statistical
Method
12a Statistical methods used to compare groups for primary
and secondary outcomes
12b Methods for additional analyses, such as subgroup
analyses and adjusted analyses
Results
Participants
(a flow
diagram
strongly
recommende
d)
13a For each group, the numbers of participants who were
randomly assigned, received intended treatment, and
were analysed for the primary outcome
13b For each group, losses and exclusions after
randomisation, together with reasons
Recruitment 14a Dates defining the periods of recruitment and follow-up
14b Why the trial ended or was stopped16-05-2014 66
Section/
Topic
Item
No
Checklist Reported
on Pg no
Baseline data 15 A table showing baseline demographic and clinical
characteristics for each group
Number
analyzed
16 For each group, number of participants (denominator)
included in each analysis and whether the analysis was
by original assigned groups
Outcomes&
estimation
17a For each primary and secondary outcome, results for
each group, and the estimated effect size and its
precision (such as 95% confidence interval)
17b For binary outcomes, presentation of both absolute and
relative effect sizes is recommended
Ancillary
analysis
18 Results of any other analyses performed, including
subgroup analyses and adjusted analyses, distinguishing
pre-specified from exploratory
harms 19 All important harms or unintended effects in each group
(for specific guidance see CONSORT for harms)
16-05-2014 67
Section/
Topic
Item
No
Checklist Reported
on Pg no
Discussion
Limitations 20 Trial limitations, addressing sources of potential bias,
imprecision, and, if relevant, multiplicity of analyses
Generalizabili
ty
21 Generalisability (external validity, applicability) of the
trial findings
Interpretation 22 Interpretation consistent with results, balancing benefits
and harms, and considering other relevant evidence
Other
information
Registration 23 Registration number and name of trial registry
Protocol 24 Where the full trial protocol can be accessed, if available
Funding 25 Sources of funding and other support (such as supply of
drugs), role of funders16-05-2014 68
 Flow chart
16-05-2014 69
References:
 Textbook of Preventive and Social Medicine by K. Park
 ctri.nic.in
 ClinicalTrials by Stuart J Pocock
 edx.org/ harvard
16-05-2014 70
16-05-2014 71
ThankYou

Mais conteúdo relacionado

Mais procurados

Introduction to clinical research - II
Introduction to clinical research - IIIntroduction to clinical research - II
Introduction to clinical research - IIPradeep H
 
clinical trials types and design
clinical trials types and designclinical trials types and design
clinical trials types and designUttara Joshi
 
Presentation working on clinical trials
Presentation working on clinical trialsPresentation working on clinical trials
Presentation working on clinical trialsSarah Henter
 
Key Concepts of Clinical Research & Clinical Trial
Key Concepts of Clinical Research & Clinical Trial Key Concepts of Clinical Research & Clinical Trial
Key Concepts of Clinical Research & Clinical Trial SWAROOP KUMAR K
 
Case Report Form (CRF)
Case Report Form (CRF)Case Report Form (CRF)
Case Report Form (CRF)Neelam Shinde
 
Clinical research ppt,
Clinical research   ppt,Clinical research   ppt,
Clinical research ppt,Malay Singh
 
Informed consent in Clinical Trials
Informed consent in Clinical TrialsInformed consent in Clinical Trials
Informed consent in Clinical TrialsKaushik Mukhopadhyay
 
A presentation on different phases of Clinical Trials, Investigational New Dr...
A presentation on different phases of Clinical Trials, Investigational New Dr...A presentation on different phases of Clinical Trials, Investigational New Dr...
A presentation on different phases of Clinical Trials, Investigational New Dr...Gagandeep Jaiswal
 
Clinical trials Phase3 ppt
Clinical trials Phase3 pptClinical trials Phase3 ppt
Clinical trials Phase3 pptSUDEEP
 
Clinical trials history
Clinical trials historyClinical trials history
Clinical trials historyPradeep H
 
Introduction to clinical trials
Introduction to clinical trialsIntroduction to clinical trials
Introduction to clinical trialsShriyaDeshpande5
 
Clinical Research Presentation
Clinical Research PresentationClinical Research Presentation
Clinical Research Presentationdeepikashankar
 
Case Report Form (CRF) Design Tips
Case Report Form (CRF) Design TipsCase Report Form (CRF) Design Tips
Case Report Form (CRF) Design TipsPerficient
 

Mais procurados (20)

Clinical research
Clinical researchClinical research
Clinical research
 
Introduction to clinical research - II
Introduction to clinical research - IIIntroduction to clinical research - II
Introduction to clinical research - II
 
Clinical Trials - An Introduction
Clinical Trials - An IntroductionClinical Trials - An Introduction
Clinical Trials - An Introduction
 
clinical trials types and design
clinical trials types and designclinical trials types and design
clinical trials types and design
 
ICH GCP
ICH GCPICH GCP
ICH GCP
 
Presentation working on clinical trials
Presentation working on clinical trialsPresentation working on clinical trials
Presentation working on clinical trials
 
Key Concepts of Clinical Research & Clinical Trial
Key Concepts of Clinical Research & Clinical Trial Key Concepts of Clinical Research & Clinical Trial
Key Concepts of Clinical Research & Clinical Trial
 
Turacoz - Clinical Study Report
Turacoz - Clinical Study ReportTuracoz - Clinical Study Report
Turacoz - Clinical Study Report
 
Case Report Form (CRF)
Case Report Form (CRF)Case Report Form (CRF)
Case Report Form (CRF)
 
Clinical research ppt,
Clinical research   ppt,Clinical research   ppt,
Clinical research ppt,
 
Informed consent in Clinical Trials
Informed consent in Clinical TrialsInformed consent in Clinical Trials
Informed consent in Clinical Trials
 
Clinical Research
Clinical ResearchClinical Research
Clinical Research
 
ICH GCP
ICH GCPICH GCP
ICH GCP
 
Clinical trials
Clinical trialsClinical trials
Clinical trials
 
A presentation on different phases of Clinical Trials, Investigational New Dr...
A presentation on different phases of Clinical Trials, Investigational New Dr...A presentation on different phases of Clinical Trials, Investigational New Dr...
A presentation on different phases of Clinical Trials, Investigational New Dr...
 
Clinical trials Phase3 ppt
Clinical trials Phase3 pptClinical trials Phase3 ppt
Clinical trials Phase3 ppt
 
Clinical trials history
Clinical trials historyClinical trials history
Clinical trials history
 
Introduction to clinical trials
Introduction to clinical trialsIntroduction to clinical trials
Introduction to clinical trials
 
Clinical Research Presentation
Clinical Research PresentationClinical Research Presentation
Clinical Research Presentation
 
Case Report Form (CRF) Design Tips
Case Report Form (CRF) Design TipsCase Report Form (CRF) Design Tips
Case Report Form (CRF) Design Tips
 

Destaque

Glossary Of Clinical Trials Terms
Glossary Of Clinical Trials TermsGlossary Of Clinical Trials Terms
Glossary Of Clinical Trials TermsMersedeh Arvaneh
 
Monitoring plan and basic monitoring visits: everything that a cra needs to know
Monitoring plan and basic monitoring visits: everything that a cra needs to knowMonitoring plan and basic monitoring visits: everything that a cra needs to know
Monitoring plan and basic monitoring visits: everything that a cra needs to knowTrialJoin
 
PR 15-149 (+) Ethical Use of Human Subjects in Infectious Disease Research - ...
PR 15-149 (+) Ethical Use of Human Subjects in Infectious Disease Research - ...PR 15-149 (+) Ethical Use of Human Subjects in Infectious Disease Research - ...
PR 15-149 (+) Ethical Use of Human Subjects in Infectious Disease Research - ...Arthur O Anderson MD
 
Statistical analysis of clinical data isi 30 01 07
Statistical analysis of clinical data isi 30 01 07Statistical analysis of clinical data isi 30 01 07
Statistical analysis of clinical data isi 30 01 07Bhaswat Chakraborty
 
진단적 인식의 논리적 구조
진단적 인식의 논리적 구조진단적 인식의 논리적 구조
진단적 인식의 논리적 구조a7309dcb
 
Tuskegee Experiment
Tuskegee ExperimentTuskegee Experiment
Tuskegee ExperimentDUKE
 
Art therapy cbt presentation revised
Art therapy cbt presentation revisedArt therapy cbt presentation revised
Art therapy cbt presentation revisedroger Rogerl
 
Estimating the Maximum Safe Starting Dose for First-in-Human Clinical Trials
Estimating the Maximum Safe Starting Dose for First-in-Human Clinical TrialsEstimating the Maximum Safe Starting Dose for First-in-Human Clinical Trials
Estimating the Maximum Safe Starting Dose for First-in-Human Clinical TrialsMaRS Discovery District
 
The Role Of Art Therapy In Healing
The Role Of Art Therapy In HealingThe Role Of Art Therapy In Healing
The Role Of Art Therapy In Healingcbyma
 
Clinical research associate performance appraisal
Clinical research associate performance appraisalClinical research associate performance appraisal
Clinical research associate performance appraisalrobynbarnes65
 
Art Therapy by sonya Carrillo
Art Therapy by sonya CarrilloArt Therapy by sonya Carrillo
Art Therapy by sonya CarrilloSonya Carrillo
 
Code of ethics in clinical trial
Code of ethics in clinical trialCode of ethics in clinical trial
Code of ethics in clinical trialUrmila Aswar
 
Art Therapy
Art TherapyArt Therapy
Art Therapymek5102
 

Destaque (20)

Glossary Of Clinical Trials Terms
Glossary Of Clinical Trials TermsGlossary Of Clinical Trials Terms
Glossary Of Clinical Trials Terms
 
Monitoring plan and basic monitoring visits: everything that a cra needs to know
Monitoring plan and basic monitoring visits: everything that a cra needs to knowMonitoring plan and basic monitoring visits: everything that a cra needs to know
Monitoring plan and basic monitoring visits: everything that a cra needs to know
 
PR 15-149 (+) Ethical Use of Human Subjects in Infectious Disease Research - ...
PR 15-149 (+) Ethical Use of Human Subjects in Infectious Disease Research - ...PR 15-149 (+) Ethical Use of Human Subjects in Infectious Disease Research - ...
PR 15-149 (+) Ethical Use of Human Subjects in Infectious Disease Research - ...
 
The basics of clinical trials
The basics of clinical trialsThe basics of clinical trials
The basics of clinical trials
 
Statistical analysis of clinical data isi 30 01 07
Statistical analysis of clinical data isi 30 01 07Statistical analysis of clinical data isi 30 01 07
Statistical analysis of clinical data isi 30 01 07
 
Sample size calculation final
Sample size calculation finalSample size calculation final
Sample size calculation final
 
진단적 인식의 논리적 구조
진단적 인식의 논리적 구조진단적 인식의 논리적 구조
진단적 인식의 논리적 구조
 
Tuskegee Experiment
Tuskegee ExperimentTuskegee Experiment
Tuskegee Experiment
 
Art therapy cbt presentation revised
Art therapy cbt presentation revisedArt therapy cbt presentation revised
Art therapy cbt presentation revised
 
Estimating the Maximum Safe Starting Dose for First-in-Human Clinical Trials
Estimating the Maximum Safe Starting Dose for First-in-Human Clinical TrialsEstimating the Maximum Safe Starting Dose for First-in-Human Clinical Trials
Estimating the Maximum Safe Starting Dose for First-in-Human Clinical Trials
 
Monitoring Visits
Monitoring VisitsMonitoring Visits
Monitoring Visits
 
The Role Of Art Therapy In Healing
The Role Of Art Therapy In HealingThe Role Of Art Therapy In Healing
The Role Of Art Therapy In Healing
 
4 gaidhane observational studies
4 gaidhane observational studies4 gaidhane observational studies
4 gaidhane observational studies
 
Toxicity
ToxicityToxicity
Toxicity
 
Clinical research associate performance appraisal
Clinical research associate performance appraisalClinical research associate performance appraisal
Clinical research associate performance appraisal
 
Art Therapy by sonya Carrillo
Art Therapy by sonya CarrilloArt Therapy by sonya Carrillo
Art Therapy by sonya Carrillo
 
Code of ethics in clinical trial
Code of ethics in clinical trialCode of ethics in clinical trial
Code of ethics in clinical trial
 
Sample size estimation
Sample size estimationSample size estimation
Sample size estimation
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
Art Therapy
Art TherapyArt Therapy
Art Therapy
 

Semelhante a Clinical Trials

Clinical Trial Safety Monitoring.pptx
Clinical Trial Safety Monitoring.pptxClinical Trial Safety Monitoring.pptx
Clinical Trial Safety Monitoring.pptxDnyanshreeTijare1
 
Good clinical practise ppt
Good clinical       practise pptGood clinical       practise ppt
Good clinical practise pptkabir ahmad
 
Clinical Trial Registration
Clinical Trial RegistrationClinical Trial Registration
Clinical Trial RegistrationPallav Singhal
 
ICH GCP by Yogesh Yadav.pptx
ICH GCP by Yogesh Yadav.pptxICH GCP by Yogesh Yadav.pptx
ICH GCP by Yogesh Yadav.pptxyogesh532361
 
GCP-Good Clinical Practice
GCP-Good Clinical PracticeGCP-Good Clinical Practice
GCP-Good Clinical PracticeANANT NAG
 
Laboratory Activ Participant To Clinical Trials [Tryb ZgodnośCi]
Laboratory Activ Participant To Clinical Trials [Tryb ZgodnośCi]Laboratory Activ Participant To Clinical Trials [Tryb ZgodnośCi]
Laboratory Activ Participant To Clinical Trials [Tryb ZgodnośCi]michaldysko
 
Regulatory and Timeline Advantages for Early Clinical Research in The Netherl...
Regulatory and Timeline Advantages for Early Clinical Research in The Netherl...Regulatory and Timeline Advantages for Early Clinical Research in The Netherl...
Regulatory and Timeline Advantages for Early Clinical Research in The Netherl...QPS Holdings, LLC
 
Clinical trial registration: where & why ?
Clinical trial registration: where &  why  ?Clinical trial registration: where &  why  ?
Clinical trial registration: where & why ?Ahmed-Refat Refat
 
GCP and EC Training (2).ppt
GCP and EC Training (2).pptGCP and EC Training (2).ppt
GCP and EC Training (2).pptgayathrivd1
 
Good Clinical Practice and Pharmacovigilance
Good Clinical Practice and PharmacovigilanceGood Clinical Practice and Pharmacovigilance
Good Clinical Practice and PharmacovigilanceMd. Zakaria Faruki
 
Good clinical practice by vijay
Good clinical practice by vijayGood clinical practice by vijay
Good clinical practice by vijayvijaypv
 
Origin and principles of international conference on harmonization- Good clin...
Origin and principles of international conference on harmonization- Good clin...Origin and principles of international conference on harmonization- Good clin...
Origin and principles of international conference on harmonization- Good clin...AbhishekJoshi312
 
Clinical Trials Registry
Clinical Trials RegistryClinical Trials Registry
Clinical Trials Registrybiinoida
 
Disclosures in Clinical Trials
Disclosures in Clinical TrialsDisclosures in Clinical Trials
Disclosures in Clinical TrialsRajendra Dhande
 
ICH E6 GCP revision
ICH E6 GCP revisionICH E6 GCP revision
ICH E6 GCP revisionAnkit verma
 

Semelhante a Clinical Trials (20)

Clinical Trial Safety Monitoring.pptx
Clinical Trial Safety Monitoring.pptxClinical Trial Safety Monitoring.pptx
Clinical Trial Safety Monitoring.pptx
 
ICH GCP
ICH GCPICH GCP
ICH GCP
 
Good clinical practise ppt
Good clinical       practise pptGood clinical       practise ppt
Good clinical practise ppt
 
Clinical Trial Registration
Clinical Trial RegistrationClinical Trial Registration
Clinical Trial Registration
 
ICH GCP by Yogesh Yadav.pptx
ICH GCP by Yogesh Yadav.pptxICH GCP by Yogesh Yadav.pptx
ICH GCP by Yogesh Yadav.pptx
 
Clic
ClicClic
Clic
 
GCP-Good Clinical Practice
GCP-Good Clinical PracticeGCP-Good Clinical Practice
GCP-Good Clinical Practice
 
Laboratory Activ Participant To Clinical Trials [Tryb ZgodnośCi]
Laboratory Activ Participant To Clinical Trials [Tryb ZgodnośCi]Laboratory Activ Participant To Clinical Trials [Tryb ZgodnośCi]
Laboratory Activ Participant To Clinical Trials [Tryb ZgodnośCi]
 
Regulatory and Timeline Advantages for Early Clinical Research in The Netherl...
Regulatory and Timeline Advantages for Early Clinical Research in The Netherl...Regulatory and Timeline Advantages for Early Clinical Research in The Netherl...
Regulatory and Timeline Advantages for Early Clinical Research in The Netherl...
 
Clinical trial registration: where & why ?
Clinical trial registration: where &  why  ?Clinical trial registration: where &  why  ?
Clinical trial registration: where & why ?
 
GCP and EC Training (2).ppt
GCP and EC Training (2).pptGCP and EC Training (2).ppt
GCP and EC Training (2).ppt
 
GCP
GCPGCP
GCP
 
Careers In Clinical Research
Careers In Clinical ResearchCareers In Clinical Research
Careers In Clinical Research
 
Good Clinical Practice and Pharmacovigilance
Good Clinical Practice and PharmacovigilanceGood Clinical Practice and Pharmacovigilance
Good Clinical Practice and Pharmacovigilance
 
Good clinical practice by vijay
Good clinical practice by vijayGood clinical practice by vijay
Good clinical practice by vijay
 
Gcp
GcpGcp
Gcp
 
Origin and principles of international conference on harmonization- Good clin...
Origin and principles of international conference on harmonization- Good clin...Origin and principles of international conference on harmonization- Good clin...
Origin and principles of international conference on harmonization- Good clin...
 
Clinical Trials Registry
Clinical Trials RegistryClinical Trials Registry
Clinical Trials Registry
 
Disclosures in Clinical Trials
Disclosures in Clinical TrialsDisclosures in Clinical Trials
Disclosures in Clinical Trials
 
ICH E6 GCP revision
ICH E6 GCP revisionICH E6 GCP revision
ICH E6 GCP revision
 

Mais de Menaal Kaushal

Chemicals in your food
Chemicals in your foodChemicals in your food
Chemicals in your foodMenaal Kaushal
 
Current scenario of vbd in india
Current scenario of vbd in indiaCurrent scenario of vbd in india
Current scenario of vbd in indiaMenaal Kaushal
 
Bivariate linear regression
Bivariate linear regressionBivariate linear regression
Bivariate linear regressionMenaal Kaushal
 
Qualitative research second copy corrected
Qualitative research  second copy correctedQualitative research  second copy corrected
Qualitative research second copy correctedMenaal Kaushal
 
Breastfeeding& special cases
Breastfeeding& special casesBreastfeeding& special cases
Breastfeeding& special casesMenaal Kaushal
 
Dengue epidemiology& case management
Dengue epidemiology& case managementDengue epidemiology& case management
Dengue epidemiology& case managementMenaal Kaushal
 

Mais de Menaal Kaushal (10)

Chemicals in your food
Chemicals in your foodChemicals in your food
Chemicals in your food
 
Women empowerment
Women empowermentWomen empowerment
Women empowerment
 
Operational research
Operational researchOperational research
Operational research
 
Emporiatrics
EmporiatricsEmporiatrics
Emporiatrics
 
Current scenario of vbd in india
Current scenario of vbd in indiaCurrent scenario of vbd in india
Current scenario of vbd in india
 
Bivariate linear regression
Bivariate linear regressionBivariate linear regression
Bivariate linear regression
 
Hpv vaccine
Hpv vaccineHpv vaccine
Hpv vaccine
 
Qualitative research second copy corrected
Qualitative research  second copy correctedQualitative research  second copy corrected
Qualitative research second copy corrected
 
Breastfeeding& special cases
Breastfeeding& special casesBreastfeeding& special cases
Breastfeeding& special cases
 
Dengue epidemiology& case management
Dengue epidemiology& case managementDengue epidemiology& case management
Dengue epidemiology& case management
 

Último

FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
Microbiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptxMicrobiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptxkitati1
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxkomalt2001
 
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptxGood Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptxLikeways
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
Pregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdfPregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdfMedicoseAcademics
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets barmohitRahangdale
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...
Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...
Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...bkling
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
Physiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid ArthritisPhysiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid ArthritisNilofarRasheed1
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondSujoy Dasgupta
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismusChandrasekar Reddy
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptxWINCY THIRUMURUGAN
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .Mohamed Rizk Khodair
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 

Último (20)

FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
Microbiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptxMicrobiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptx
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptx
 
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptxGood Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptx
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
Pregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdfPregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdf
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...
Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...
Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
Physiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid ArthritisPhysiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid Arthritis
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and Beyond
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismus
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 

Clinical Trials

  • 1. ClinicalTrials Dr Menaal Kaushal JR II Department of S.P.M. S. N. Medical College Agra 16-05-2014
  • 2. Types of Studies Epidemiological Studies Observational Descriptive Analytical Interventional/ Experimental RCT FieldTrial Community Trial 16-05-2014 2
  • 3. Why ClinicalTrials?  Gold standard with aTotality of Evidence:  Lab Study- High Precision  Epidemiological Study- High Relevance  Designed to elucidate Most Appropriate Treatment for the FUTURE PATIENTS  Should be done only in existence of CLINICAL EQUIPOISE  So, during enrollment the researcher must ensure Absence of THERAPEUTIC MISCONCEPTION among the participants.  Also ensure the non-existence of Oxymoron: THERAPEUTIC RESEARCH 16-05-2014 3
  • 4. From Lab to Clinics to Community- the Developmental Process Funnel Drug Discovery Pre clinical Phase I FIH Phase II POC Phase III Post approval Trials- Phase IV 10,000 compounds 10- 15 yrs $ 1 billion 1 compound Bench to Bed SideTranslational Blocks T0- Discovery Science T1 Phase Clinical/Translational Research NOT ClinicalTrial BorderlineTrial ClinicalTrial T2 T3 16-05-2014 4
  • 5. Pre Clinical Phase  Safety Testing- Toxicity and Physiological Response to the new Compound is assessed  Organs targeted include:  Cardio- vascular  Neuro- muscular  Respiratory  + Other Organs and systems depending on the compound’s action  Dose Dependence  Potential for Reversibility16-05-2014 5
  • 6. Toxicity studies  AcuteToxicity: determine overdose effects  Repeated Dose Toxicity: maximum duration of clinical trial 16-05-2014 7
  • 7. MRSD Determination  HED= animal’s NOAEL (mg/kg)* Wt (Animal) 1-0.62  A 10 fold Safety margin is usually used, so:  MRSD= HED/ Safety factor  Maximum tolerated Dose (MTD) needs to be estimated where the Dose limiting toxicity has a certain probability ( )Wt (Human) 16-05-2014 8
  • 8. Dose Response Curve Increasing Dose (mg/kg)------------> Probabilityofadverseevents P(DLT)----------> 0 1 0.33 MTD 16-05-2014 9
  • 9. Phase I- FIHTrial  Healthy volunteers are given a single dose in a controlled environment (In- patient settings)  Volunteers usually paid  Risks are kept to be minimum  What needs to be assessed is:  Safety  Pharmacokinetics  Pharmacodynamics  Route and Rate of administration  Fixing up the end points  Physiologic effects in humans16-05-2014 10
  • 10. POC Study  Patients having the disease of interest, are enrolled  Volunteers not paid  Moderate (or even serious) risks are acceptable  Done to assess:  The Dose response  Safety  Pathophysiology  Limited observation about efficacy 16-05-2014 11
  • 11. Steps in Conducting a Phase III Clinical Trial  Design Phase  Research Question- FINER Criteria, PICOT style  Study Designs  Ethical Considerations& GCP Guidelines  Registering with CTRI  Latest DGCA Guidelines-Video Record Every Consent  Sample Size, Clearly defined Inclusion- Exclusion criteria 16-05-2014 12
  • 12. Steps in Conducting a Phase III Clinical Trial  Implementation Phase  Randomization v/s Random Allocation  Blinding  Control- StandardTreatment v/s Placebo  Monitoring& DSMB- InterimAnalysis  Analytical Phase  ITT v/s Per protocol analysis  CONSORT Guidelines 16-05-2014 13
  • 13. Research Question  FINER; PICOT  Following need to be considered:  Effect Size  Composite endpoints  Surrogate End Points  Study duration  Secondary Questions  Sub group Hypothesis  Natural History Studies 16-05-2014 14
  • 14. Study Designs  Two group parallel design-The Look ahead trial (T2DM obese pts on Diabetes support& education v/s active, intensive lifestyle modification)  Multi group parallel design-The Re-ly trial (Atr Fib pts on warfarin v/s dabigatran 110mg v/s dabigatran 150 mg)  Factorial design-The SUPPORTTrial (very premature neonates were randomized into Early surfactant v/s early CPAP and O2 Saturation 85% v/s 95%)  Cross over design- Pts can be compared on themselves. E.g. Hemophilia trial. No carry over between the two treatment periods- Rest period is needed16-05-2014 15
  • 15. The History Behind Ethics Nuremberg Code- 1946 Declaration of Helsinki- 1964 Council for International Organizations of Medical SciencesCIOMS- 1982 International Conference on Harmonization – Good clinical practice (ICH-GCP)- 1996 16-05-2014 16
  • 16. Historical Perspectives  Council for International Organizations of Medical Sciences (CIOMS) and WHO (1982) – International ethical guidelines for biomedical research involving human subjects  Revised – 1993, 2002  International Conference of Harmonization – Good clinical practice (ICH-GCP)-1996)  International ethical and scientific quality standard for designing, conducting, recording and reporting trials involving human subjects. 16-05-2014 18
  • 17. 13 Principles of GCP 1. Ethics (Declaration of Helsinki) 2. Risk Benefit analysis 3. Trial subjects (rights and safety) 4. Investigational product (Information support study) 5. Scientifically sound 6. Compliance (IRB review)16-05-2014 19
  • 18. 7. Qualified physician to provide medical care 8. Trial staff (trained in protocol) 9. Informed consent 10. Data (reporting, interpretation, verification) 11. Confidentiality 12. Good manufacturing practice of the investigational product 13. QualityAssurance of all aspects of protocol 16-05-2014 20
  • 19. 7 Components of the Ethics: 1. Social or Scientific value 2. ScientificValidity 3. Fair Subject Selection 4. Favorable risk- benefit ratio 5. Independent review 6. Informed Consent 7. Respect for potential and enrolled subjects 16-05-2014 21
  • 20. Ethics in Trials  During Phase I Trials, 95% of the times, participating patients do not benefit from theTrial  The probability (chance) of having any benefit 5%  Risk of fatal complication 5%  While there may be a significant chance of benefit in Phase IIITrial 16-05-2014 22
  • 23. Informed Consent - Elements  Information  Patient/subject information sheet  Comprehension  Simple and understandable language  Local language translations  Voluntariness  Consent 16-05-2014 27
  • 24. Informed Consent  Community studies – Consent needed from  Community – group consent  Individuals  Children  Parent/guardian  Assent of child to his/her capability  Mentally Ill  Close biological relative  Legally authorized person  Certificate from psychiatrist 16-05-2014 28
  • 25. Importance Of Clinical Trials Registration  To ensure transparency , accountability and to increase public trust in the conduct of clinical research.  Clinical trial registration and results reporting would help ensure unbiased public records on safety and efficacy of drugs.  All clinical trials should be registered before the enrolment of the first patient and all results made publicly available. 16-05-2014 29
  • 26. Registration of Trials Globally  At the 58th WHA held on 25th May 2005 WHO had set up of an International Clinical Trial Registry Platform (ICTRP), a one-stop search portal for searching registers worldwide.  The ICTRP recommended 20 key points as Trial Registration data Set that need to be publicly declared before the enrolment of the first patient.  In the 59th General Assembly of the World Medical Association, 2008, in its revision of the Declaration of Helsinki among other modifications, specifies that:  “Every clinical trial must be registered in a publicly accessible database before recruitment of the first subject.” 16-05-2014 30
  • 27. CTR- I  Till 2006, there was no national registry of clinical trials in India  On July 20, 2007, ICMR through its National Institute of Medical Statistics (NIMS) formed Clinical Trials Registry – India (CTRI) www.ctri.nic.in with financial support from DST andWHO.  The CTRI has additional data points over the ICTRP’s recommended 20 point data set:  Later these additional points were borrowed from CTR- I and were inculcated in the WHO’s ICTRP. 16-05-2014 31
  • 28. Registration Data Set of the CTRI 1. Public Title of Study 2. Scientific Title of Study, Acronym, if any 3. Secondary IDs, (UTN, Protocol No etc) 4. Principal Investigator’s Name and Address* 5. Contact Person (Scientific Query) 6. Contact Person (Public Query) 7. Source/s of Material or Monetary Support 8. Primary Sponsor 9. Secondary Sponsor 10. Countries of Recruitment 11. Site/s of study 12. Name of Ethics Committee and approval status 13. Regulatory Clearance obtained from DCGI * Optional fields 14.Health Condition/Problem studied 15.Study Type 16.Intervention and Comparator agent 17.Key inclusion/Exclusion Criteria 18.Method of generating randomization sequence* 19.Method of allocation concealment* 20.Blinding and masking* 21.Primary Outcome/s 22.Secondary Outcome/s 23.Target sample size 24.Phase of Trial 25.Date of first enrollment 26.Estimated duration of trial 27.Status of Trial 28.Publication details* 29.Brief Summary Additional items of CTRI 16-05-2014 32
  • 30.  It is housed at the National Institute of Medical Statistics, ICMR, New Delhi.  Trial registration is purely online, paperless process and free of charge  The CTRI software application was modified and implemented on 15th March 2011. Clinical Trials Registry – India 16-05-2014 34
  • 31. Objectives of CTRI  To establish a public record system by registering all clinical trials on health products including:  Drugs  Devices  Vaccines  Herbal drugs  It makes the information available to both public and healthcare professionals in an unbiased, scientific and timely manner.  To create a complete, authentic and readily available data of all ongoing and completed clinical trials. 16-05-2014 35
  • 32. Objectives of CTRI  To provide a corrective system against “positive results bias” and “selective reporting” of research results to peer review publication.  To increase awareness and accountability of all the participants of the clinical trials and also for public access:  Trial registration empowers the public and offer patients the choice of enrolling in a clinical trial to gain access to latest breakthrough treatment options.  To promote training, assistance and advocacy for clinical trials by creating database and modules of study for various aspects of clinical trials and its registration. 16-05-2014 36
  • 33. Registration of clinical trials under CTR- I is recommended by: 1. Drugs Controller General (India): Made mandatory since June 2009 2. Editors of Indian Biomedical Journals; 3. Ethics Committees of various institutions, AIIMS, CMC, Sir Ganga Ram Hospital etc. 16-05-2014 37
  • 35.  CTRI currently accepts registration of:  Prospective trials  Ongoing  Completed trials  Terminated trials  Registered trials are flagged as:  Trial registered prospectively  Trial registered retrospectively  Terminated trial registered 16-05-2014 41
  • 37. Registering Trials during PG Thesis CTRI encourages registration of trials being conducted as part of post- graduation thesis work  This would help  Ensure ethical standards  Prevent unnecessary duplicate research  Raise the standard of research  Enable better exchange of data and ideas 16-05-2014 47
  • 39. Methodology Enrollment Criteria Ascertainment of Primary End Point Treatment A (Test) Treatment B (Control) Quality: Adherence Missing Data 16-05-2014 53
  • 40. Sample Size Calculations n= 2 ṕ (1-ṕ) (Zα/2+Zβ)2/ Δ2 Where: Δ= pc- pt ṕ= (pc+ pt)/ 2 At α= 0.05, Zα/2= 1.96 At β= 0.20, Zβ= 0.84 16-05-2014 54
  • 41. Sample Size Calculations n= 2 (Zα/2+Zβ)2/ log (λc/λt)2 Where: λ= survival probability At α= 0.05, Zα/2= 1.96 At β= 0.20, Zβ= 0.84 16-05-2014 55
  • 42. Randomization  Unrestricted Randomization: may produce treatment groups of different sizes  Randomized Permuted Block  Stratified Randomized Permuted Block  Cluster Randomization 16-05-2014 56
  • 43. Unrestricted Randomization Probability--------------------- Number of heads from 20 tosses--------------------16-05-2014 57
  • 44. Relativeefficiency Proportion allocated toTreatment A 50%0% 100% Relative Efficiency of Unbiased Allocation 16-05-2014 58
  • 45. Randomized Permuted Blocks ABAB AABB BBAA BABA ABBA BAAB 16-05-2014 59
  • 47. Analysis  Intent to treat  Modified Intent to treat  Per protocol Analysis  On assignedTt  Fully compliant with study domain  As treated Analysis Best Active- Interventional Compromised Observational 16-05-2014 61
  • 48. Analysis to Study Outcome  Binary (HTN or Normotensive)  Measurable (BP reading)  Time to event (at what time during the follow up, has the event occurred)  Other outcomes: No. of episodes (e.g. no of exaggeration episodes of asthma, while on treatment) 16-05-2014 62
  • 49. CONSORT (Con solidated S tandards o f R eportingT rials) statement Section/Topic Item No Checklist Reported on Pg no Title& Abstract 1a Identification as a randomised trial in the title 1b Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts) Introduction 2a Scientific background and explanation of rationale Background& Objectives 2b Specific objectives or hypotheses Method Trial Design 3a Description of trial design (such as parallel, factorial) including allocation ratio 3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons 16-05-2014 63
  • 50. Section/Topic Item No Checklist Report ed on Pg no Participants 4a Eligibility criteria for participants 4b Settings and locations where the data were collected Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were actually administered outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed 6b Any changes to trial outcomes after the trial commenced, with reasons Sample size 7a How sample size was determined 7b When applicable, explanation of any interim analyses and stopping guidelines16-05-2014 64
  • 51. Section/Topic Ite m No Checklist Reported on Pg no Randomization Sequence 8a Method used to generate the random allocation sequence Generation 8b Type of randomisation; details of any restriction (such as blocking and block size) Allocation Concealment mechanism 9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned Implementatio n 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how 16-05-2014 65
  • 52. Section/ Topic Item No Checklist Reported on Pg no 11b If relevant, description of the similarity of interventions Statistical Method 12a Statistical methods used to compare groups for primary and secondary outcomes 12b Methods for additional analyses, such as subgroup analyses and adjusted analyses Results Participants (a flow diagram strongly recommende d) 13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome 13b For each group, losses and exclusions after randomisation, together with reasons Recruitment 14a Dates defining the periods of recruitment and follow-up 14b Why the trial ended or was stopped16-05-2014 66
  • 53. Section/ Topic Item No Checklist Reported on Pg no Baseline data 15 A table showing baseline demographic and clinical characteristics for each group Number analyzed 16 For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups Outcomes& estimation 17a For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval) 17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended Ancillary analysis 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) 16-05-2014 67
  • 54. Section/ Topic Item No Checklist Reported on Pg no Discussion Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses Generalizabili ty 21 Generalisability (external validity, applicability) of the trial findings Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence Other information Registration 23 Registration number and name of trial registry Protocol 24 Where the full trial protocol can be accessed, if available Funding 25 Sources of funding and other support (such as supply of drugs), role of funders16-05-2014 68
  • 56. References:  Textbook of Preventive and Social Medicine by K. Park  ctri.nic.in  ClinicalTrials by Stuart J Pocock  edx.org/ harvard 16-05-2014 70